Biodexa Pharmaceuticals Plc ADR (BDRX)

$5.48 +0.37 (7.24%)
Market Cap 3.17M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.04
Volume 13,200
Avg Vol 222,136
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 61%
Beta 0.98
Analysts Sell
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
Love_To_Learn
Love_To_Learn Nov. 14 at 8:27 PM
$BDRX COMMUNICATING WITH $SINT REROUTING OFF THE 4.31%
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 7:52 PM
$ABEO 4.42 ANOMALY FULLY ONLINE NOW SHIFTING IT TO COORDIANTE WITH MARKETS $SLS $CYCU $BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 7:51 PM
$ABEO WEAPONIZING THIS 4.42 ANOMALY BELONGING TO $SLS AS $CYCU FINISHIES OUT THE SEQUENCE AS SLS 1.44******* TRANSMITTING METADATA TO BEUD $BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 7:46 PM
$CYCU 6.52/6.54 6.62 6.64 CODING $SLS $BDRX !
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 7:46 PM
$CYCU CODING $SLS WHILE THEY R SENDING METADATA TO BEUD $BDRX
2 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 2:31 PM
$BTC.X $BDRX final move with your reliance for good ! $SLS shifting pandora
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 1:47 PM
$GCTK $PBM $ENVB $BDRX $AIFU shift
0 · Reply
JeanBets
JeanBets Nov. 13 at 8:15 PM
$BDRX 🦍🦍🦍💰
0 · Reply
Hodler9
Hodler9 Nov. 11 at 8:03 PM
$AMYY $BDRX $COOT $ELAB $USSH ELAB breaking out, better get your tickets for a wild ride🤞
0 · Reply
PaulLaurent
PaulLaurent Nov. 11 at 7:13 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $BDRX $ELAB $COOT $USSH $AMYY
1 · Reply
Latest News on BDRX
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 12 days ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 5 weeks ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 2 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 2 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 3 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 3 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 3 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

ADR Ratio Change

Jul 15, 2025, 4:30 PM EDT - 4 months ago

ADR Ratio Change

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 4 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 5 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 5 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 5 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 5 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 5 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 5 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 6 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 6 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 6 months ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 6 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 7 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 7 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 8 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 8 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 9 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 9 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 9 months ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 9 months ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 9 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 10 months ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 17, 2024, 7:30 AM EDT - 1 year ago

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Biodexa Announces Successful Appeal of Nasdaq Delisting

Love_To_Learn
Love_To_Learn Nov. 14 at 8:27 PM
$BDRX COMMUNICATING WITH $SINT REROUTING OFF THE 4.31%
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 7:52 PM
$ABEO 4.42 ANOMALY FULLY ONLINE NOW SHIFTING IT TO COORDIANTE WITH MARKETS $SLS $CYCU $BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 7:51 PM
$ABEO WEAPONIZING THIS 4.42 ANOMALY BELONGING TO $SLS AS $CYCU FINISHIES OUT THE SEQUENCE AS SLS 1.44******* TRANSMITTING METADATA TO BEUD $BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 7:46 PM
$CYCU 6.52/6.54 6.62 6.64 CODING $SLS $BDRX !
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 7:46 PM
$CYCU CODING $SLS WHILE THEY R SENDING METADATA TO BEUD $BDRX
2 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 2:31 PM
$BTC.X $BDRX final move with your reliance for good ! $SLS shifting pandora
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 1:47 PM
$GCTK $PBM $ENVB $BDRX $AIFU shift
0 · Reply
JeanBets
JeanBets Nov. 13 at 8:15 PM
$BDRX 🦍🦍🦍💰
0 · Reply
Hodler9
Hodler9 Nov. 11 at 8:03 PM
$AMYY $BDRX $COOT $ELAB $USSH ELAB breaking out, better get your tickets for a wild ride🤞
0 · Reply
PaulLaurent
PaulLaurent Nov. 11 at 7:13 PM
📈⚠️ Stocks with Recent Surge in Short Interest ⚠️📈 $BDRX $ELAB $COOT $USSH $AMYY
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 9:29 PM
$CYCN WHERE PANDORA 1ST HALF WAS TAKEN OUT BY BEUD $BDRX PRE RS
0 · Reply
moneytra1n
moneytra1n Nov. 10 at 8:31 PM
$BDRX No chance. Youre a fraud.
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 8:19 PM
$BDRX CREATING A NEW ROLE AND IDENTITY FOR U MY BEUD
1 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 8:15 PM
$BDRX 5.8* TEMO RES FINISHING METADATA TRANSFER TO BELOVED
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 8:15 PM
$BDRX SHE HAS NEVER KNOWN A LIFE NOT INVOLVING CRYPTO PORTAL SHE WILL B A BIT VOLATILE FOR NOW
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 8:09 PM
$KXIN EXECUTIGN OLD BEUD FROM POST RS $BDRX
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 8:02 PM
$KXIN CODING 1.44 SPECIAL DETONATION SEQUENCE $BDRX OPENING CRYPT PORTAL AS A WHOLE ACCESSING $BTC.X FROM TREASURY
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 7:53 PM
$BDRX THIS WILL B THE LAST TIME U WILL B NEEDED FOR THIS IN THIS MANNER AS PANDORA WILL EFFECTIVELY TAKE OVER AFTER TODAY IN THIS REGARD
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 10 at 7:52 PM
$BDRX 1.44 OLD BEUD USING KXIN ! CALLING U MY BEUD REQUIRE U TO OPEN THE CRYPTO PORTAL
0 · Reply
Inda
Inda Nov. 5 at 6:34 PM
$BDRX time for investors to notice the news : « Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion » 🔥🔥🔥🔥
0 · Reply
Bullet47
Bullet47 Nov. 5 at 12:48 PM
$BDRX should run by end of week, market will adjust hopefully. Been red since the beginning of the week with CTA news
0 · Reply
Inda
Inda Nov. 5 at 11:26 AM
$CDT & $BDRX time for reversal 🔥🔥🔥🔥🔥
0 · Reply